Quoin Pharmaceuticals, Ltd.
QNRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,603 | $3,308 | $2,673 | $1,563 |
| G&A Expenses | $5,926 | $6,071 | $6,585 | $4,500 |
| SG&A Expenses | $5,926 | $6,071 | $6,585 | $4,500 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,528 | $9,379 | $9,258 | $6,063 |
| Operating Income | -$9,528 | -$9,379 | -$9,258 | -$6,063 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $566 | $692 | -$124 | -$15,400 |
| Pre-Tax Income | -$8,962 | -$8,687 | -$9,381 | -$21,463 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,962 | -$8,687 | -$9,381 | -$21,463 |
| % Margin | – | – | – | – |
| EPS | -66.85 | -337.47 | -22.97 | -28,543.2 |
| % Growth | 80.2% | -1,369.2% | 99.9% | – |
| EPS Diluted | -66.85 | -337.47 | -22.97 | -28,543.2 |
| Weighted Avg Shares Out | 134 | 26 | 404 | 2 |
| Weighted Avg Shares Out Dil | 134 | 26 | 404 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $558 | $695 | $96 | $0 |
| Interest Expense | $0 | $0 | $714 | $1,090 |
| Depreciation & Amortization | $100 | $104 | $104 | $104 |
| EBITDA | -$9,428 | -$9,275 | -$8,563 | -$20,268 |
| % Margin | – | – | – | – |